Exchange: NASDAQ·Updated 08:43 PM EDT

SLS News

News
all
press releases
SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals
J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.
Stocktwits
SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals
J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.
Stocktwits
More News
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
The third-quarter earnings season kicked off this week, with Goldman Sachs, Citigroup, Wells Fargo and JPMorgan Chase reporting their results.
Stocktwits
Why Are Nasdaq Futures Rising Premarket? MU, IREN, SLS, NIO, ASTS, WFF Stocks In Focus
On Stocktwits, retail sentiment toward SPY and QQQ has moderated to ‘bullish’.
Stocktwits
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.
Stocktwits
SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal Hopes
A new study of 2,610 AML patients found a median survival of 11.4 months with Venetoclax-based therapy versus 8.2 months with hypomethylating drugs alone.
Stocktwits
Nasdaq, S&P 500, Dow Futures Rise Ahead Of Jobs Report: NKE, META, RKLB, MRNA, SLS, TSLA Stocks In Focus
On Stocktwits, retail sentiment toward SPY and QQQ remained ‘bullish’ ahead of jobs data.
Stocktwits
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.
Stocktwits
SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027
Retail investors speculated that Sellas’ office lease through September 2027 provides stability for clinical results and potential deal discussions.
Stocktwits
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Stocktwits
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits

Advertisement|Remove ads.